Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 petosemtamab vs investigator's choice in previously treated metastatic/recurrent HNSCC
jRCT2031240485Phase 3Active, not recruiting
- Sponsor
- Genmab
- Start
- Nov 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of petosemtamab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Genmab. Primary endpoints: objective response rate (ORR) and overall survival (OS). Started Nov 2024; status: active, not recruiting.
02
Drugs
petosemtamab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on jRCT2031240485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240485.